22 September 2021
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
21 September 2021: Piscataway, New Jersey; Oxford and Manchester, UK; Mahwah, New Jersey. Today, Infinity BiologiX, LLC (IBX), Cytox Ltd, and Vanguard Pharma announce the launch of the IBX Alzheimer’s Risk Test, powered by genoSCORETM. Physicians are able to pre-register to order the test, which will be available from early October 2021.
The new, non-invasive, test is the first physicians use only, clinically available and validated “polygenic” test, assessing over 100,000 genetic variations, to predict the risk of cognitive decline due to Alzheimer’s disease. The test only requires a simple saliva or blood sample, enabling individuals not wishing or easily able to attend healthcare settings, to provide a suitable sample from home.
Physicians can use the Alzheimer’s Risk Test to identify patients most at risk of cognitive decline, prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. The results of the test can guide lifestyle changes and use of drug therapy to delay the onset of disease symptoms.
Dr. Richard Pither, CEO of Cytox, commented: “Modifiable factors account for more than 40% of the risk for dementia. Consequently, it is important that clinicians confronted with patients with early cognitive concerns, have the appropriate tools to assist in understanding the future risk of disease progression to guide lifestyle advice and clinical management. This new test can support planning, by reducing the burden of additional testing in lower-risk patients, and targeting monitoring and prevention approaches to those most likely to benefit.”
The following chart shows the well-documented modifiable risk factors associated with Alzheimer’s disease, and executable actions that patients can take to mitigate the risks, with the potential to delay the onset of symptoms, and slow disease progression.
Robin Grimwood, IBX CEO, explained: “We are proud to partner with Cytox and Vanguard Pharma bringing the lab capabilities and expertise of the IBX team to bear on this cutting-edge solution. Enabling physicians to support their patients with the most clinically appropriate treatments is at the heart of what we do as an organization. This new test will provide physicians with a critical tool to stimulate lifestyle changes and therapy guidance prior to the onset of Alzheimer’s disease symptoms.”
Kevin Danylchuk, President of Vanguard Pharma added: “We are honored to be part of the launch of this exciting and innovative test. As part of the launch activities for the Alzheimer’s Risk Test, we will be hosting a number of different educational forums - both live and online that discuss how this test can be optimally used in clinical practice. Our aim is to ensure that the test is widely available to clinicians across the country who can use it to help guide patient needs and care decisions.”